Your medical history
Semaglutide is a GLP-1 receptor agonist that suppresses appetite and drives significant weight loss by changing how your brain and gut regulate hunger and satiety
Where the anti-obesity benefit is included in the employer plan, Harvard Pilgrim requires prior authorization with BMI 30 or higher (or 27 with a weight-related comorbidity such as hypertension, T2D, dyslipidemia, or sleep apnea), documented lifestyle program participation, and demonstrated weight-loss progress for renewal
These injectable medications, part of a class called GLP-1 receptor agonists, have shown impressive results in helping people shed pounds
How long should I wait post-surgery to restart
June 1, 2020: FDA is alerting civilian health care professionals and emergency responders of 4 additional DuoDote lots that are no longer useable and should be properly disposed of